Biomarkers Europe 2024

30 September - 01 October 2024 | Basel, Switzerland

Gain insights into Biomarker approaches & accelerate timelines in drug development for oncology and immuno-related therapies

Event Page - Hero Banner 3
Overview Biomarkers Precision Oncology
+co-located event:
Spatial Biology

Formed of the 3rd Annual Biomarkers Europe and 2nd Annual Precision Oncology Europe Congresses, Biomarkers Europe 2024 is focused on driving the advancement of biomarkers within the fields of oncology and immunotherapy.

The co-located events provide a specialized platform to explore the most innovative technologies and approaches for biomarker validation & Identification, biomarker analysis, applications in precision oncology & patient treatment in clinical trials.

With over 50 presentations, these two-day congresses provide multiple opportunities for engaging scientific insights, valuable networking, and interactive panel & workshop discussions.

Over 500 leading industry experts and clinicians will engage on biomarker end points, personalised patient treatment and companion diagnostics development including early detection technologies & liquid biopsies.

3rd Annual Biomarkers Europe Congress

Addressing challenges in biomarker analysis to accelerate timelines in drug development including the role of safety and efficacy biomarkers . Discover novel approaches into optimising biomarker analysis through effective assay development, as well as utilising the latest multiplexed tools impacting biomarker research and validation.

  • Acquire knowledge about how biomarker approaches are utilized in drug discovery and translational sciences for oncology and immuno-related therapies.
  • Explore how companies accelerate timelines and reduce risk in drug development. Presentations consider the latest applications of Biomarker Analysis – Multiplex Technology Application & Translational Research in oncology & Immunological disorders
  • Gain insights into emerging bioanalysis approaches, assay development, and what can be translated in the clinic

Agenda at a Glance


3rd Annual Biomarkers Europe Congress

  • Day One | Track 1: Biomarkers For Diagnostic Development & Clinical Development
  • Day One | Track 2: Identification, Qualification & Validation of Biomarkers in Translational Studies
  • Day Two: Data-Driven Approaches for Biomarker Analysis in Drug Development

2nd Annual Precision Oncology Europe Congress

Bringing together experts In Oncology And Cancer Care, Clinical Research, and Drug Development To Explore application in diagnosis, stratification & prognosis in oncology, and advancing personalized treatment to improve patient outcomes.

  • Showcasing the latest technologies and clinical studies in multi-cancer early detection and minimal residual disease testing
  • Learn about molecular characterization of tumour for targeted therapy selection
  • Explore biomarker and companion diagnostics discovery, and development
  • Gain insights from genomics-enabled clinical trials for tailored cancer drug development

Agenda at a Glance


2nd Annual Precision Oncology Europe Congress

  • Day One: Multi-Cancer Early Detection Techniques & Companion Diagnostics for Precision Oncology
  • Day Two: Digital Technologies For Advancing Biomarkers In The Clinic & Personalized Patient Treatments 

3rd Annual Spatial Biology Europe Congress

Attendees of Biomarkers Europe 2024 also have access to Spatial Biology Europe 2024

Explore Spatial Biology Europe 2024: Unlocking Future Insights in Spatial Biology Research

Join leaders, experts and researchers at the 3rd Annual Spatial Biology Europe Congress, connecting global academic & research organisations as well as pharma representatives for high-level discussions on the latest innovations in spatial research & technologies. Forward looking visionary leaders will discuss the current state of the industry, market trends and future growth areas aiding the application of spatial technologies in the clinic.

  • Take a deep dive into image analysis, AI-powered imaging, and utilising digital pathology for spatial biology. Key opinion leaders will be providing insights into computational image analysis, multiplexed digital pathology, and the utilisation of AI & machine learning within spatial transcriptomic studies 
  • Discuss the latest innovations in spatial bioinformatics and data analytics. Presentations will delve into the use of spatial data in biology, modelling cell-cell communications, and computational algorithms for spatial analysis. A focused workshop will investigate how to overcome the challenges of spatial data integration
  • Gain comprehensive insights into novel application areas for spatial biology. This event will cover the applications of spatial data across a variety of therapeutic areas including neuroimmunology, oncology, cardiology and more. Discussions will also involve strategies for making spatially targeted therapeutics more precise
  • Hear from leading innovators utilizing spatial biology in pharma. See how leading pharmaceutical companies are beginning to integrate spatial biology into R&D to accelerate timelines and move towards the clinic

Agenda at a Glance


  • Day One | Track 1: Spatial Multi Omics Techniques & Approaches
  • Day One | Track 2: Image Analysis, AI-Powered Imaging & Digital Pathology for Spatial Biology
  • Day Two | Track 1: Spatial Bioinformatics, Data Analytics and Interpretation
  • Day Two | Track 2: Applications of Spatial Research & Technologies in Biology

What to Expect

500

leading pharma, biotech, & academic delegates

12
hours of presentations, discussions & interactive content
9
hours of networking breaks, including speed networking & refreshments
100
hours of pre-arranged 1-2-1 meetings, facilitating business growth
Interactive Presentations
Exhibition Hall
Networking Drinks
Poster Display
Event App Swapcard

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 50 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

NEW FOR 2024!

Executive-Level Panel Discussions

These closed door sessions will include insights from key opinion leaders spearheading innovation in Biomarkers & Precision Oncology. Places are limited — secure your spot now by selecting a session during registration.

Closed Door Panel Discussion: 
Challenges in Translating Exploratory Biomarkers into the Clinic

Moderated by:
GUNTHER JANSEN, Senior Director, Precision Medicine & Data Science, Novartis

Closed Door Workshop: 
Advancements in Liquid Biopsy 
Technologies for Precision Oncology

Presented by:
NOLWEN GUIGAL-STEPHAN, Head of 
Clinical Biomarkers, Servier

ED SCHUURING, Clinical Scientist in 
Molecular Pathology, University Medical Centre Groningen

Closed Door Panel Discussion: How to Bridge the Gap Between the Bench & Bedside: Applications of Precision Medicine in a
Healthcare Setting

Stay tuned for Moderator details

Companies Represented Include

Meet Our Expert Speakers

Biomarkers Europe 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Amanda Heslegrave
Senior Research Fellow,
University College London
Benjamin Weber
Vice President Translational Research,
Novo Nordisk
Brian Lockhart
Global Head of Companion Diagnostics,
Servier
Cornelia Wilson
Reader and Academic Laboratory Director,
Canterbury Christ Church University
Dirk Kemming
Medical Director Diagnostics Europe,
Daiichi Sankyo Europe
Ed Schuuring
Clinical Scientist in Molecular Pathology,
University Medical Center Groningen
Gunther Jansen
Head of Multimodal Data & Analytics,
Novartis
Joanna Janus
Research Programme Manager (Early Detection and Prevention),
Cancer Research UK
Marine Garrido
Translational leader,
Bayer
Olga Nissan
C EO,
Protica Bio
Philip Beer
Chief Scientific Officer,
Step Pharma
Shashank Saran
Associate Director,
AstraZeneca
Aitana Sogorb-Esteve
Senior Research Fellow,
University College London
Andrew Janowczyk
Assistant Professor,
Emory University
Axel Ducret
expert scientist,
F. Hoffmann-La Roche Ltd
Bernhard Reis
Biomarker Lead,
F. Hoffmann-La Roche Ltd.
Bernhard Reis
Expert Biomarker & Translational Medicine Leader; Group Head Biomarker Strategy,
F. Hoffman-La Roche Ltd.
Christian Ruiz
Senior Lecturer; Chief Scientific Officer,
University of Basel; Moonlight AI
Christophe Le Tourneau
Medical Oncologist,
Institut Curie
Dylan Powell
Lecturer Public Health and Innovation,
Stirling University
Fatima Sanfourche
Senior Director of QA & RA Compliance for Medical Devices and eHealth,
Bayer
Guillaume Desachy
Head Of Biometrics,
AstraZeneca
Jacques Colinge
Professor,
University of Montpellier, France
Jan Christoph Brase
Global Precision Medicine Leader,
Bayer
Jehad Charo
Principal scientist - Biomarker Experimental Medicine Leader,
Hoffmann La Roche Ltd
Jon Krell
Senior Clinical Lecturer and Honorary Consultant in Medical Oncology,
Imperial College London
Jose MG Izarzugaza
Head of Department,
Novo Nordisk
Mario Richter
Director II DMPK-BA Global Biomarker Lead,
AbbVie Deutschland GmbH & Co. KG
Maximilian Breitner
Laboratory Head Bioanalytics,
Sandoz
Nolwen Guigal-Stephan
Head of Clinical Biomaker Development,
Servier Monde
Pekka Ruusuvuori
Assistant Professor, PI in Bioimage informatics Institute of Biomedicine,,
Turku University
Rodrigo Toledo
Group Leader,
Vall d'Hebron Institute of Oncology
Thomas Jensen
CEO,
Allarity Therapeutics

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

Hope for New Prognostic Biomarkers & Therapeutic Options From Tumour Metabolism-Targeting Breast Cancer Study

Understanding the interplay between the tumour microenvironment and immunometabolic states could unlock a wealth of therapeutic targets and biomarkers.

New Zika-Specific Synthetic Biomarker Can Differentiate From Dengue Virus

A test that identifies Zika distinct from dengue could make a definite impact to expectant mothers and reproductive-age women that are at risk from the mosquito-borne disease.

New MND Early Diagnostic Test: a 'Game-Changer' for Research on the Disease

Detecting the aggregation of TDP-43 spells a new diagnostic tool for MND.

Enhancing Patient Care: Exploring the Role of Digital Biomarkers in Patient-Centric Healthcare

Digital biomarkers, collected from wearables and apps, are reshaping patient-centered healthcare with real-time insights and personalized care. Challenges like data privacy and interoperability require collaboration between healthcare, tech, and regulators for full integration.

How Digital Biomarkers Can Enhance Pathologies and Patient Care

Digital biomarkers hold promise for healthcare, offering improved rare disease detection and cost reduction, with the potential for future implementation in clinical healthcare settings.

How Multiplexing Could Increase the Availability of Blood Biomarkers for Classifying Neurodegenerative Disorders

Recent studies have used multiplex blood biomarker information from patients to distinguish individual patient subgroups for neurodegenerative diseases, helping to stratify patients by their pathology.

Plan Your Visit

Congress Center Basel
MCH Swiss Exhibition (Basel) Ltd. Messeplatz 21, CH-4058 Basel

By Rail

Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)

By Tram

From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.

By Air

EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/

By Car

Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.

Information regarding accommodation for this event will be added here soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Biomarkers Europe 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch